Fate Therapeutics Drops To US$3.41, Yet Insiders May Have Sold Too Early
Fate Therapeutics Drops To US$3.41, Yet Insiders May Have Sold Too Early
Even though Fate Therapeutics, Inc. (NASDAQ:FATE) has fallen by 12% over the past week , insiders who sold US$222k worth of stock over the past year have had less luck. Insiders might have been better off holding onto their shares, given that the average selling price of US$4.27 is still below the current share price.
儘管fate therapeutics公司(納斯達克:fate)在過去一週下跌了12%,但在過去一年內出售價值222,000美元的股票的內部人員運氣不太好。內部人士如果堅持持有股份可能會更好,因爲平均售價4.27美元仍低於當前股價。
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.
雖然我們絕不建議投資者僅基於公司董事所做的事情來作出決策,但我們認爲密切關注內部人士所做的事情是完全合理的。
The Last 12 Months Of Insider Transactions At Fate Therapeutics
在Fate therapeutics過去12個月的內部交易中,創始人J· Wolchko進行了最大規模的內部交易。那次單筆交易價值63000美元,每股股價爲4.37美元。儘管我們通常不喜歡看到內部人員出售股票,但如果銷售價格較低,則更令人擔憂。令人欣慰的是,這筆交易的價格遠高於當前股價3.41美元。因此,這可能並不能告訴我們內部人員對當前股價的感受。
The Founder, J. Wolchko, made the biggest insider sale in the last 12 months. That single transaction was for US$63k worth of shares at a price of US$4.37 each. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$3.41. So it may not tell us anything about how insiders feel about the current share price.
創始人J. Wolchko進行了過去12個月中最大的內部交易。這一單交易價值6.3萬美元,每股價格爲4.37美元。我們通常不喜歡看到內部人員進行賣出交易,但如果交易價格低於當前價格,則更加令人擔憂。令人欣慰的是,這筆交易以遠高於當前股價3.41美元的價格進行,這可能並不能告訴我們內部人員對當前股票價格的看法。
In the last year Fate Therapeutics insiders didn't buy any company stock. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
納斯達克GM:fate的內部交易量爲2024年6月19日。
![insider-trading-volume](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240619/0-3d288f31f8ee9a8fc8414fa1294d4cf7-0-ea64fab5f79325f10b45617a391045de.png/big)
If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.
如果您和我一樣,您就不會錯過這個免費的小盤股票列表,這些股票不僅被內部人士購買,而且估值也很有吸引力。
Insider Ownership Of Fate Therapeutics
Fate therapeutics的內部交易可能告訴我們什麼? 最近三個月沒有內部交易-這並不意味着什麼。Fate therapeutics內部人員的交易並未給我們帶來太多鼓舞。我們沒有發現高持股權內部人員持股的跡象,這並沒有給我們帶來任何安慰。了解內部人員的所有權和交易狀況固然重要,但在做出任何投資決策之前,我們還要考慮該股票面臨的風險。每個公司都有風險,我們已發現Fate therapeutics的三個警告信號(其中一個可能非常嚴重!)您需要了解。
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. Our data indicates that Fate Therapeutics insiders own about US$6.0m worth of shares (which is 1.5% of the company). Whilst better than nothing, we're not overly impressed by these holdings.
但請注意:Fate therapeutics可能不是最好的買入股票。因此,請查看此免費的有高roe和低債務的有趣公司列表。
What Might The Insider Transactions At Fate Therapeutics Tell Us?
《聚焦》:命運治療的內部交易能告訴我們什麼?
There haven't been any insider transactions in the last three months -- that doesn't mean much. We don't take much encouragement from the transactions by Fate Therapeutics insiders. And we're not picking up on high enough insider ownership to give us any comfort. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Every company has risks, and we've spotted 3 warning signs for Fate Therapeutics (of which 1 is potentially serious!) you should know about.
在過去的三個月中沒有任何內部交易發生,但這並不意味着什麼。我們並不對Fate Therapeutics內部人員的交易感到鼓舞,也沒有足夠高的內部持股比例來讓我們感到安心。儘管了解內部人員的所有權和交易情況很重要,但在做出任何投資決策之前,我們還需要考慮股票面臨的風險。每家公司都存在風險,我們發現Fate Therapeutics存在3個警告信號(其中1個可能很嚴重!)你應該了解。
But note: Fate Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
但請注意:Fate therapeutics可能不是最好的買入股票。因此,請查看此免費的有高roe和低債務的有趣公司列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,也可以發送電子郵件至editorial-team@simplywallst.com